Azole Antifungal Resistance in Candida albicans and Emerging Non-albicans Candida Species

By D. Sanglard, E. Berkow, S. Whaley, J. Rybak, A. Nishimoto, K. Barker, P. David Rogers. Frontiers in Microbiology, 2017

815 citations recorded by the source corpus.

Within the limited antifungal armamentarium, the azole antifungals are the most frequent class used to treat Candida infections. Azole antifungals such as fluconazole are often preferred treatment for many Candida infections as they are inexpensive, exhibit limited toxicity, and are available for oral administration. There is, however, extensive documentation of intrinsic and developed resistance to azole antifungals among several Candida species. As the frequency of azole resistant Candida isolates in the clinical setting increases, it is essential to elucidate the mechanisms of such resistance in order to both preserve and improve upon the azole class of antifungals for the treatment of Candida infections. This review examines azole resistance in infections caused by C. albicans as well as the emerging non-albicans Candida species C. parapsilosis, C. tropicalis, C. krusei, and C. glabrata and in particular, describes the current understanding of molecular basis of azole resistance in these fungal species.

Subfields: Epidemiology, Infectious Diseases

View Paper: https://www.semanticscholar.org/paper/9f6ea4da691fd9c8caa448294efb254423be194f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

  1. M. Ghannoum
  2. K. E. Pristov

In Infectious Diseases

  1. M. Ghannoum
  2. K. E. Pristov

Citations in the corpus